Recently, there has been a much greater understanding of the complex biological and social (historical, political, economic, and cultural) dimensions of antimicrobial resistance (AMR), and it has influenced proposals to address them. Whilst AMR control is still dominated by measuring total and individual antibiotic usage and performance indicators, including resistance, implementation of interventions that are meaningful for the income setting now takes into account inequality, including health, water, sanitation, and hygiene systems. Not only are there differences in Low- and middle-income countries (LMICs) compared to High-Income countries (HIC), but there are marked differences in approach to stewardship for primary and secondary care. Tackling resistance is still largely dominated by the reduction in the use of antibiotics. The necessity of complex approaches to this complex problem, engaging all aspects of public health as well as the necessity of innovation to embrace a more holistic approach, need to be applied.
This article collection is aimed at understanding the relationship between innovation and access in the 21st century in the context of the antibiotics recently developed and those in the pipeline. We will be focusing on public health need in different settings and builds on identifying patient populations who badly need small steps in innovations rather than reflecting on failures of the pipeline and future disaster. The aim is to make being part of the successes achieved and the achievable introduction of new antibiotics more attractive to both investors and scientists.
The Research Topic welcomes the submission of original research, methods, reviews, and perspective articles, focusing on, but limited to, the latest pharmaceutical innovations, novel antibiotics tailored for regions facing AMR challenges and to combat the worldwide antibiotic resistance crisis as well, application the evidence base required for registration and beyond, for efficacy, resistance, safety, patient acceptance using Real-World Data to personalize treatments, recognizing the complexity HIC, LMICs, procedures for addressing the issue, and potential ethical considerations in anti-infective policy-making.
Dr. Gabbay is a co-founder of tranScrip. All other Topic Editors declare no competing interests.
Keywords:
AMR, antibiotic stewardship, public health, novel therapies, community pharmacies
Important Note:
All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
Recently, there has been a much greater understanding of the complex biological and social (historical, political, economic, and cultural) dimensions of antimicrobial resistance (AMR), and it has influenced proposals to address them. Whilst AMR control is still dominated by measuring total and individual antibiotic usage and performance indicators, including resistance, implementation of interventions that are meaningful for the income setting now takes into account inequality, including health, water, sanitation, and hygiene systems. Not only are there differences in Low- and middle-income countries (LMICs) compared to High-Income countries (HIC), but there are marked differences in approach to stewardship for primary and secondary care. Tackling resistance is still largely dominated by the reduction in the use of antibiotics. The necessity of complex approaches to this complex problem, engaging all aspects of public health as well as the necessity of innovation to embrace a more holistic approach, need to be applied.
This article collection is aimed at understanding the relationship between innovation and access in the 21st century in the context of the antibiotics recently developed and those in the pipeline. We will be focusing on public health need in different settings and builds on identifying patient populations who badly need small steps in innovations rather than reflecting on failures of the pipeline and future disaster. The aim is to make being part of the successes achieved and the achievable introduction of new antibiotics more attractive to both investors and scientists.
The Research Topic welcomes the submission of original research, methods, reviews, and perspective articles, focusing on, but limited to, the latest pharmaceutical innovations, novel antibiotics tailored for regions facing AMR challenges and to combat the worldwide antibiotic resistance crisis as well, application the evidence base required for registration and beyond, for efficacy, resistance, safety, patient acceptance using Real-World Data to personalize treatments, recognizing the complexity HIC, LMICs, procedures for addressing the issue, and potential ethical considerations in anti-infective policy-making.
Dr. Gabbay is a co-founder of tranScrip. All other Topic Editors declare no competing interests.
Keywords:
AMR, antibiotic stewardship, public health, novel therapies, community pharmacies
Important Note:
All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.